{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-001433","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.353900+00:00","generated_at":"2026-05-28T02:06:34.633162+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"C4 Therapeutics unveils 2025 milestones; cash runway extended into 2027","bullets":["Cash, cash equivalents and marketable securities as of Dec 31, 2024 expected to fund operations into 2027.","Cemsidomide Phase 1 dose escalation in multiple myeloma and NHL to complete in 2H 2025; next-phase studies to start early 2026.","CFT1946 monotherapy dose escalation in BRAF V600 solid tumors to complete 1H 2025; Phase 1 data in melanoma and CRC expected 2H 2025.","CFT8919 Phase 1 data from partner Betta in China will inform future development outside China."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-001433","json":"https://secwatch.observer/filing/0001628280-25-001433.json","markdown":"https://secwatch.observer/filing/0001628280-25-001433.md","text":"https://secwatch.observer/filing/0001628280-25-001433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025001433/0001628280-25-001433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025001433/cccc-20250114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:06:34.633162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}